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1. INTRODUCTION 
 
Preterm birth is defined as birth between the age of viability and 37 
completed weeks of gestation. It includes deliveries between 24 to 36 weeks 
and 6 days gestation and also includes all births with birth weight above 
500gms. The incidence varies from 5% to 8% among most developed and 
developing countries. Infants between 34 and 36 weeks account for 
approximately 75 percent of all preterm births. 
 
Preterm birth cause an increased perinatal mortality, long term 
morbidity and affects health economics. India has the highest number of 
preterm births and deaths in the world.    
 
The four main reasons for preterm birth are: 
1. Induction of labor for fetal or maternal causes or the infant is 
delivered by  caesarean delivery before onset of labor – 30 to 35% 
2. Idiopathic  preterm labour with intact membranes – 40 to 45% 
3. Idiopathic preterm premature rupture of membranes – 30 to 35% 
4. Higher order pregnancy. (ovulation induction) 
 
  
Aims and Objectives 
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2. AIM OF THE STUDY 
 
 To evaluate salivary progesterone as a predictor of preterm birth and 
compare it with transvaginal cervical length in asymptomatic high risk 
women. 
  
Overview 
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3.  OVERVIEW 
DEFINITION 
Preterm labour is defined as the onset of regular, painful, frequent, 
uterine contractions causing progressive effacement and dilation of cervix 
from the period of viability and earlier than gestational age of 37 completed 
weeks.  
 
RISKS FOR PRETERM BIRTH 
  Idiopathic preterm birth is the most common cause of preterm birth .  
Other factors are  PPROM, genetic, infection, nutrition,  behaviour and the 
environment. 
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ANTECEDANTS AND CONTRIBUTING FACTORS FOR 
PRETERM BIRTH 
1. Threatened abortion 
Vaginal bleeding in early pregnancy (6 to 13 weeks) were associated 
with subsequent preterm labor. (Weiss and associates, 2004). 
2. Social factors 
Lower socioeconomic status, Smoking, less weight gain in 
pregnancy,  advancing maternal age, short stature, certain drugs and 
deficiency of vitamin C increases the risk of preterm labor. 
3. Racial - Ethnic factors 
African –American and Afro-caribbean are at higher risk of preterm 
deliveries (Goldenberg and colleagues, 2008b). 
 
4. Work during pregnancy 
Occupational factors like prolonged standing or walking, strenuous 
work and long weekly hours  increases the rsk of preterm labor. (Casnueva, 
2005 and all their colleagues). 
5. Genetic Factors 
  Chorioamnionitis is potentiated by immunoregulatory genes in cases 
of preterm delivery due to infection (varner and Esplin, 2005). 
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6. Periodontal disease 
Periodontal disease increases the risk of preterm birth- odds ratio 2.83 
(Goepfert and co-workers, 2004) 
 
7. Birth defects 
         Congenital anomalies were associated with preterm birth and low birth 
weight. (First trimester evaluation of risk (FASTER) trial, Delan and 
colleagues, 2007). 
 
8. Interval between pregnancies 
Interpregnancy interval lesser than 18 months and more than 59 
months has increased risk of preterm birth  ( Conde-Agudelo , co-workers, 
2006) 
 
9. Prior preterm birth  
 
Recurrent spontaneous preterm births according to  
prior outcome 
Birth outcome Second birth ≤34 weeks in percent 
First birth ≥35 weeks 5 
First birth ≤34 weeks 16 
First and second birth ≤34 weeks 41 
Data from 15,683 women delivering their first and subsequent pregnancies at 
Parkland Hospital. Adapted from Bloom and associates (2001) with permission 
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10. Infection 
 
25-40% of preterm birth is contributed by intrauterine infection. 
 
 
The two microorganisms implicated , ureaplasma urealyticum and 
mycoplasma hominis, induce release of inflammatory cytokines like 
interleukins and tumour necrosis factor (TNF). This in turn, stimulate the 
production of prostaglandin which stimulates uterine contraction and/or 
matrix degrading enzymes which results in preterm prelabor rupture of 
membranes. 
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11. Bacterial Vaginosis 
It leads to preterm labor, preterm prelabour rupture of membranes, 
chorio amnionitis and amniotic fluid infection (Hiller,1995; larki,1992; 
Leitich,2003 a,b, and all their colleagues). Chronic stress, ethnic differences 
and frequent douching cause bacterial vaginosis (Culhane and co-workers, 
2002, Ness and associates, 2002) 
 
12. Medical Disorders 
Anaemia, liver disease, asthma, hypertensive disorder, renal disease, 
tuberculosis, cardiac disease, diabetes, hyperthyroidism, malaria, 
hyperpyrexia also cause preterm birth. 
 
13. Iatrogenic  
  Elective premature induction due to fetal or maternal indication. 
Induction with wrong estimation of gestational age also contribute to 
preterm birth. 
 
14. Miscellaneous 
Abdominal surgeries during pregnancy, severe trauma and drugs like 
quinine increases the risk of preterm birth. 
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PREDICTORS OF PRETERM BIRTH: 
A. WARNING SIGNALS: 
 Menstrual like cramps 
 Dull  low backache 
 Abdominal cramps 
 Sense of pelvic pressure or heaviness in the vagina, 
 Glairy mucoid vaginal discharge 
 
B. TRANSVAGINAL SONOGRAPHY 
 The application of transvaginal sonography for cervical length has 
emerged as a recommendation by the American college of Radiology.The 
cervical length <2.5cm, funneling or widening of cervical canal, (Y, V, U 
shape), bulging of membranes in cervical canal and thinning of lower 
uterine segment can be identified.. 
 
C. BIOCHEMICAL MARKERS: 
1. Fetal fibronectin: 
 It is a glycoprotein produced  by hepatocytes, fibroblast, endothelial 
cells, and fetal amnion. It is present in amniotic fluid and the extra villous 
tropho decidual interface. The substance is present in cervicovaginal fluid 
before 20 weeks of gestation,  and reappear only after spontaneous rupture 
of membranes at term. Fetal fibronectin level of  >50 ng/ml estimated by 
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ELISA is considered as a positive predictor of preterm labour. This test has 
high sensitivity and high negative predictive value . 
 
2. Salivary estriol:  values  more than 2.3ng/ml predicts preterm labour. 
3. Serum collagenases. 
4. Tissue inhibitor of metalloproteinase (TIMP) 
5. Ferritin/ Iron ratio 
6. Relaxin. 
7. Serum triglycerides. 
8. Corticotrophin releasing hormone (CRH). 
9. Mediators of inflammation and infection. 
a. C-Reactive Protein. 
b. Leucocyte esterase. 
c. Cytokine. 
d. Amniotic fluid glucose concentration. 
e. Zinc. 
f. Lipocortin-I. 
g. Positive cultures. 
10. Salivary progesterone. 
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D. HOME UTERINE ACTIVITY MONITORING: 
Contractions are recorded by telemetry twice a day. It is costly and 
not an easily available equipment. However it is not useful in reducing the 
incidence of preterm labour.                                      
 
E. FOETAL BREATHING MOVEMENT: 
 Patients are likely to go in preterm labour within 48 hours, if absent 
fetal breathing movements are detected in real time ultrasonogram. 
 
F. RISK SCORING SYSTEM: 
Papiemick (1974) used an elaborate scoring system for detection of 
patient more prone for spontaneous preterm labour which was later,  
modified by Creasy et al.  Those with 10 or more scores were more prone 
for preterm labour. 
 
ACOG CRITERIA: 
ACOG (1997) criteria to diagnose preterm labour: 
 Contractions of 4 in 20 minutes with progressive change in the cervix, 
 Cervical dilation more than or equal to 1cm, 
 Cervical effacement more than or equal to 80% 
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PREVENTION OF PRETERM BIRTH: 
1. Improving the socioeconomic condition. 
2. Patient education and prepregnancy counseling  regarding warning 
signals. 
3. Identifying and correcting  risk factor whenever possible-1.Proper 
nutrition, 2. Avoid smoking, alcohol, 3. Adequate rest-avoidance of 
physical and mental stress, 4. Control of medical diseases, 5. Cervical 
encirclage in proved case of cervical incompetence. 
4. Any operation in pregnant woman to be planned during second trimester. 
5. Proper assessment before induction of labour to avoid iatrogenic 
prematurity. 
6. Treat vaginal and cervical infections and asymptomatic bacteriuria in 
pregnancy . 
7. Coitus, late in pregnancy should be avoided.  
8. Prophylactic tocolysis is not indicated. 
9. Cervical Encerclage - A short cervix diagnosed by ultrasound in   
asymptomatic women might be an indication for cerclage. . 
10. Progesterone- Weekly intramuscular  injection of 250mg of 17-OH 
progesterone caproate from 20 to 36 weeks, to  high risk women  
lowered the rates of preterm birth and perinatal mortality when compared 
to placebo. 
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DIAGNOSIS OF PRETERM LABOUR 
1. Symptoms of preterm labour. 
2. Clinical examination. 
3. Ultrasonogram. 
4. Cardiotocograph 
 
MANAGEMENT OF PRETERM LABOUR 
1. Bed rest , hydration 
2. Antenatal steroid 
 12mg of betamethasone- 2 doses of intramuscular injections 24 hours 
apart or 6mg of dexamethasone - 4 doses of intramuscular injections  12 
hours apart can be given between 24 and 34 weeks of gestation  to all 
women who are prone for  preterm delivery within 7 days. 
 
3. Tocolysis 
Tocolytics are the drugs which inhibit uterine activity. They are 
a. BETA SYMPATHOMIMETICS 
       The inhibition of uterine contractions by this drug is short lived.   
 I generation: Isoxsuprine, orciprenaline, Isoprenaline 
 II generation: Ritodrine, Terbutaline, Fenoterol 
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b. MAGNESIUM SULPHATE 
   MgSO4  acts by uncoupling the depolarization contraction coupling 
(Elliott, 1983) 
Therapeutic level is 4-8mmol per liters. 
 
c. PROSTAGLANDIN SYNTHETASE INHIBITORS 
   Drugs like aspirin, indomethacin are used to prevent preterm labour 
in patients with cardiac disease and hyperthyroidism. They are not routinely 
used because of fear of PDA closure and pulmonary hypertension in fetus. 
 
d. CALCIUM CHANNEL BLOCKERS 
Nifedipine act by inhibiting the influx of extracellular calcium and 
release of intracellular calcium from the sarcoplasmic reticulum  during 
inward calcium current of action potential, reducing the tone of smooth 
muscles.  
 
e. OXYTOCIN ANTAGONIST ( ATOSIBAN ) 
 This  oxytocin analogue competitively blocks the oxytocin receptors 
and inhibits preterm labour. RCOG guidelines says that if tocolytics is 
administered, the first choice should be oxytocin antagonists followed by 
Nifedipine. 
  
14 
 
IMMEDIATE CONSEQUENCES OF PRETERM LABOUR 
Perinatal mortality: 
 Preterm labor accounts for 85% of deaths in structurally normal 
infants.   
The  survival rates for preterm babies in India are as follows: 
 26-30 Weeks - 67% 
 30-34 Weeks - 75% 
 34-38 Weeks - 94.3% 
 
Neonatal morbidity: 
     
 
The incidence of morbidities in Indian studies are  
1. Respiratory Distress Syndrome   80% 
2. Patent Ductus Arteriosus    50% 
3. Intraventricular haemorrhage   31.5% 
4. Retinopathy of Prematurity   25.2% 
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Hypothermia and hypoglycemia are common problems in preterm 
babies. Other major problems related to preterm delivery include 
intraventricular hemorrhage, periventricular leucomalacia and retinopathy of 
prematurity. 
 
LONG TERM CONSEQUENCES OF PRETERM LABOR 
Cerebral palsy, intellectual impairments and behavioral problems are 
more frequent in preterm babies. 
 
Refractive errors and strabismus are also common. Deafness occur in 
1.5-9% . 
 
There is poor feto-maternal bonding due to the psychological and 
physical stress it puts. Newborn with membrane disease or who required 
assisted ventilation may develop chronic pulmonary disease. Infants 
delivered preterm are  more prone for hospitalization in the earlier ages of 
life. Preterm male infants frequently have inguinal hernia . 
 
Dogye and colleagues (1994) reported that only 20% of preterm 
infants were actually free of impairment at 5 years of age 
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ECONOMIC CONSIDERATIONS 
The cost of acute hospital care for preterm infants is very high. 
Antenatal care for these mothers may prove costly as many of them have 
obstetrical complications. The long hospital stay adds to the economic 
burden.. After discharge from the hospital, the health care and social service 
system continue to incur substantial costs for the special needs and special 
education for these children, more so with long term morbidity. Added to 
this, the loss of productivity on the part of the parents also increases the 
economic burden. 
  
Review of Literature 
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4. REVIEW OF LITERATURE 
 
 Prematurity is the most common cause of neonatal and infant 
mortality and morbidity. The preterm newborns pose a major financial 
burden. . It is for these reasons, strategies for prediction and prevention of 
preterm labor is necessary. Several biological, clinical and sonographic 
markers have been suggested as tools for predicting preterm labor. The 
tested biological markers included cervico-vaginal fetal fibronectin level, 
human chorionic gonadotropin (hCG) level and serum corticotropin 
releasing hormone (CRH). Most of these tested markers lack either 
acceptable validity or feasibility and availability. So a quicker, cheaper, 
simpler test with greater accuracy for  predicting  preterm labor is needed, 
so that one can avoid unnecessary tocolysis and take appropriate 
intervention or refer earlier to a tertiary care centre.  
 
Goldenberg and colleagues (2008b) related pathogenesis of preterm 
labour to 
1. Withdrawal of Progesterone  
2. Initiation of Oxytocin  
3. Activation of decidua. 
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Role of Progesterone in parturition  
  The studies conducted in sheep supports progesterone withdrawal 
theory.  
 
After 6-7 week gestation, the ovary produces very little progesterone 
(Diczfalwey and Troen, 1961). 
 
After 8 weeks, the placenta secretes progesterone , and there is a 
progressive increase in serum progesterone levels. About 250mg  of 
progesterone is produced daily in late pregnancy . 
 
 
 
 The Placental trophoblast produces a large amount of progesterone 
utilizing maternal plasma cholesterol (Hellig and associates,1970), 
preferentially  LDL cholesterol (simpson and Burkhart, 1980) 
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 During pregnancy, the  concentration of 5α-dihydro progesterone in 
the plasma increases disproportionately. It is synthesized by 
syncytiotrophoblast  from precursors got from  fetus. (Dombroski and 
coworker, 1997). This increase in the progesterone metabolite and 
progesterone causes resistance to pressor agents in pregnancy. 
 
 The fall in progesterone level directly precedes the progression of  
uterine quiescence and cervical competence into uterine activation and 
cervical ripening of parturition in many species. Supplementing 
progesterone delays parturition by decreasing the uterine activity and 
continued maintenance of competency of cervix. (Challis and Lye, 1994). 
Thus the progesterone deficient myometrium is quiescent.  
 
 Teleological evidence reveals that an increased ratio of progesterone 
to estrogen is necessary for sustaining the pregnancy and that a fall in the 
progesterone to estrogen ratio results in parturition. 
 
 The estrogen acts to promote progesterone responsiveness, and thus, 
promote uterine quiescence. The estrogen receptor acting via the estrogen-
response element of the progesterone-receptor gene, induces progesterone-
receptor synthesis. 
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Progesterone increases uterine quiescence by decreasing the 
expression of contraction-associated proteins (CAPS) and inhibiting the 
expression of connexin43. 
 
Functional progesterone withdrawal or antagonism  occurs through possible 
ways: 
1. Alteration in the  expression of the  progesterone receptor (PR) protein 
isoforms, PR-A, PR-B and PR-C in the nucleus. 
2. Alteration in the  expression of membrane-bound progesterone receptors. 
3. Post translation modification of the receptor, specific to progesterone. 
4. Changes in progesterone receptor activity through variations in the 
expression of co-activators or co-repressors that directly influence 
receptor function. 
5. Inactivation of progesterone by locally produced steroid-metabolizing 
enzymes . 
 
PR-B moderates  progesterone actions, whereas PR-A and PR-C 
diminutes progesterone responsiveness. Studies show that  there is a 
transferral in the relative ratio of PR-A to PR-B , late in gestation. The ratio 
of PR-A and PR-B is altered in decidua and chorion. The receptor isoform 
in the stroma of cervix also showed variations.  PR-C to PR-B ratio is 
increased in fundus. 
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Studies reveal that 5-α reductase type 1 enzymes when expressed, 
break down progesterone to by products resulting in failure of cervix to 
ripen. There is an increase in estrogen and decrease in progesterone level, in 
deficiency of the enzyme , 20-α-hydroxy steroid dehydrogenase.   (Prekorz 
and associates, 2005). Decrease in 17β-hydroxy steroid dehydrogenase  
type 2 in the human cervix at term results in a net increase in estrogen and 
decrease in progesterone. And finally, glucocorticoids also has anti-
progestin activity ( Karalis and co-workers, 1996). 
 
With the onset of labor, the fetal-adrenal axis gets sensitized to 
adrenocorticotrophic hormones, and cortisol secretion is stimulated. 
Placental 17-α hydroxylase activity is potentiated by cortisol. This, in turn 
reduces progesterone production  and increase estrogen production.                                            
This altered  estrogen/progesterone ratio results in increased prostaglandin 
formation, thus inducing  labor. 
 
Concentrations of steroids in saliva correlates well with their serum 
concentrations and reflect the free, unconjugated, and, thus, the biologically 
active portion of the plasma hormone profile. 
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Advantages of saliva  
 Ultrafiltrate of plasma 
 Collection is easy 
 Storage  is easy 
 
Limitation 
1. Patient activity/posture, food consumption 
2. Oral lesions, abrasions, gingivitis  
 
ROLE OF ULTRASONOGRAPHY 
The word “cervix” refers to “neck of the womb”. It is the distal 
narrow and cylindrical part of the uterus, which enters the vagina at right 
angles to it. The ectocervix, the portion projecting into the vagina, also 
known as “portiovaginalis”, is convex and elliptical. It measures 3cm long 
and 2.5cm wide and opens out through the external os.  
 
The endocervical canal extends between the internal os and the 
uterine cavity.  The internal os is the  upper limit of the endocervical canal  
and opens into the uterine cavity. 
 
TRANSVAGINAL SONOGRAPHY 
 Transvaginal sonogram can be performed similar to gynaecologic 
examination. It is simple, cost-effective, reproducible and reliable method to 
assess and predict the risk of preterm delivery. 
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Limitations:  
 Incomplete or failure to empty the maternal bladder is associated with 
false measurement. 
 Increased pressure on the vaginal probe. 
 Any polyp, fibroid, cervical growth, that obscure proper imaging. 
 A poorly developed lower uterine segment. 
 
 To minimise the intra-observer variability, the below methods are 
suggested. 
 The flat dimple or an isosceles triangle seen is the internal os.. 
 The cervix should be visualized as a whole. 
 The external os gives symmetric appearance. 
 The distance from the surface of the posterior lip to the cervical canal 
is equal to the distance from the surface of the anterior lip to the cervical 
canal. 
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Trans-vaginal measurement of cervix length. 
 
These conditions when met, ensures visualization of the entire cervix 
and placement of only minimal pressure on the cervix by the transducer 
(which may falsely decrease the cervical length and create false funneling. 
Using these guidelines, the intra-observer variability decreases from 3.04 to 
1.24mm. 
 
 In primigravida population, the smaller the cervix, they were more 
prone for preterm labour. However, in the multiparous women, the internal 
os dilation was a more useful predictor.  
  
Materials and Methods 
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5. MATERIALS AND METHODS 
 
 This prospective study was done in IOG, Egmore, Chennai from 
January 2015 to March 2016.  Informed written consent was obtained from 
all participants in the study. 
 
Subject selection:  They were selected from the AN clinic, IOG 
Inclusion Criteria: 
1. Asymptomatic women with singleton pregnancy with history of 
previous preterm birth. 
2. Previous preterm prelabor rupture of membranes. 
3. Late spontaneous miscarriage (20 to 28 weeks). 
 
Exclusion Criteria: 
1. Multiple gestation. 
2. Congenital anomalies of uterus/fetus. 
3. Antepartum haemorrhage. 
4. Obstetric complications requiring iatrogenic preterm birth. 
5. Non -reassuring fetal heart rate pattern. 
6. Fetal growth restriction. 
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7. Medical disorders like hypertensive disorders of pregnancy, 
hyperglycemia in pregnancy, renal disorders, cardiac disease, chronic 
liver disease, vaginal infections, cervical cerclage. 
8. Medications affecting hormonal concentration-antipsychotics, 
corticosteroids or progesterone therapy. 
9. Tocolysis. 
10. Any addiction-smoking, alcohol. 
11. Bleeding from the gums. 
 
Screening Procedures/Visits  
 All AN women recruited were subjected to salivary progesterone 
estimation at 24 to 28 weeks. At the same time, they were subjected to 
transvaginal cervical length measurement. 
 
I)  Estimation of Salivary progesterone: 
 Following consent, after overnight fasting, mouth rinsed with water 
10 minutes before collecting saliva . A sterile, wide mouthed glass or plastic 
container  was used for collecting samples. 3 unstimulated samples were 
collected within 2 hours and pooled together. The sample was stored at or 
below -200 c within 30 minutes until the test. 
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SAMPLE PROCESSING 
 Colorless salivary samples  without any contaminants like food or 
blood were collected.  
 
Sample Collection 
 The container should be made of ultrapure polypropylene. Sample 
were collected either in the fasting state or after avoiding milk products and 
food of animal origin. Or else saliva were collected while anticipating a 
meal. Each sample should be a minimum of 0.5ml. 
 
Sample Storage and Preparation 
  Saliva samples can be stored  for 7 days at ambient temperature. 
Samples can be stored at  at  40 c for a period of up to one month. Samples 
were stored at a temperature of -200c. Before proceeding with the test, 
sample were thawed and centrifuged at least once  in order to separate the 
mucin by centrifugation for atleast 5 – 10 minutes . The clear supernatant 
layer was be used for assay.  
 
Dilution of Specimen  
The highest calibrator was (5000 pg/ml).Samples suspected to have 
greater progesterone concentrations than the highest calibrator was diluted 
with the zero calibrator.  
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METHOD OF ASSAY 
 
General instructions 
 All samples and test kits were brought to room temperature and 
mixed in such a way to avoid foaming. 
 The entire procedure was carried out uninterruptedly. 
 Separate disposable pipette tips were used for each reagents and 
samples. 
 Since absorbance depends on the incubation time and temperature, all 
containers were kept open and pipette kept ready before starting the 
procedure. 
 
Steps 
1. A sufficient  microplate wells to accommodate calibrators, controls 
and patient samples were prepared. 
2. The wells were filled  appropriately with control , sample and 100 
microlitres of each calibrator.. 
3. 50 microlitres of enzyme conjugate were pipetted into the wells. 
4. The microplate well was placed on a mixer and incubated at room 
temperature  for 60 minutes. 
5. The content in the wells were discarded and the wells rinsed with 
diluted wash solution atleast 4 times. The wash solution was removed 
with absorbent paper completely. 
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6. 200 microlitres of substrate solution was added to each of the well. 
7. Incubated in the dark  for 30 minutes without shaking. 
8. Later, stop solution was added to each well in a quantity of 50 
microlitres. 
9. The absorbance  was read within 15 minutes at 450 nm  
10. Results got in absorbance units were used to draw a standard curve  
and the concentration of progesterone in each sample got from the 
calibrator curve. 
 
STEPS OF ELISA TEST 
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II. Determination of cervical length: 
Measurement was done with the patient in dorsal position and with 
empty bladder by introducing the probe into the anterior fornix. 3 
measurements were taken and the shortest measurement was recorded.  
I) Follow up: 
Salivary progesterone estimation was done again between 29 – 32 
weeks.. Cervical length measurement was also done at the same time. They 
were followed up regularly. Post delivery, records were verified for mode of 
delivery,  gestational age at delivery,  neonatal outcome and admission to 
NICU. Mother  and newborn were followed up till discharge. 
  
Analysis of Results 
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6. ANALYSIS OF RESULTS 
 
 
No of patients enrolled in the study    - 90    
No of patients who completed the study   - 81  
No of patients who were excluded     - 9 
Final list of patients      - 81 
Total number of patients delivered preterm   - 12 
Incidence of preterm birth in this study   - 14.81% 
No of preterm babies who required NICU admission - 12 
 
 
 The datas were evaluated using Receiver operator characteristic 
curve, chi-square test,  t-test and linear regression curve. 
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RECEIVER OPERATOR CHARACTERISTIC CURVE 
SALIVARY PROGESTERONE VS OUTCOME - 24 TO 28 WKS
 
 
CERVIX LENGTH VS OUTCOME – 24 TO 28 WKS 
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SALIVARY PROGESTERONE VS OUTCOME - 29 TO 32 WKS 
 
 
CERVIX LENGTH VS OUTCOME – 29 TO 32 WKS 
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CONCLUSION 
 Sensitivity Specificity AUC Criterion 
Progesterone 24-28 
Weeks 100 94.2 0.990338 ≤3903 
Progesterone 29-32 
Weeks 100 100 1.0000 ≤2975 
Cervix 24-28 Weeks 91.7 95.7 0.973430 ≤3.1 
Cervix 29-32 Weeks 100 98.6 0.997585 ≤2.9 
 
 There is a statistical significance existing between labour outcome 
and salivary progesterone and cervical length measured between 24 to 28 
weeks and 29 to 32 weeks. 
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SALIVARY PROGESTERONE AND NEONATAL 
COMPLICATIONS  -  24 TO 28 WEEKS 
 
 
 
 
 
 
 
 
 
 
29 TO 32 WEEKS 
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CERVIX LENGTH VS NEONATAL COMPLICATIONS - 
24 TO 28 WEEKS 
 
 
29 TO 32 WEEKS 
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CONCLUSION 
 Sensitivity Specificity AUC Criterion 
Progesterone 
24-28 Weeks 100 93.9 0.982955 ≤3703 
Progesterone 
29-32 Weeks 100 98.5 0.998106 ≤2935 
Cervix 
24-28 Weeks 100 93.9 0.977273 ≤3.1 
Cervix 
29-32 Weeks 100 97 0.982955 ≤2.7 
 
There is a statistical significance existing between salivary 
progesterone and cervical length measured between 24 to 28 weeks and 29 
to 32 weeks with respect to neonatal complications. 
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Age Group Vs Outcome 
Crosstab 
 
Outcome 
Term Pre-term Total 
Age Group 
 
Up to 25 years 
Count 26 6 32 
% within Age Group 81.3% 18.8% 100.0% 
% within Outcome 37.7% 50.0% 39.5% 
% of Total 32.1% 7.4% 39.5% 
26-30 years 
Count 32 4 36 
% within Age Group 88.9% 11.1% 100.0% 
% within Outcome 46.4% 33.3% 44.4% 
% of Total 39.5% 4.9% 44.4% 
31 years & 
above 
Count 11 2 13 
% within Age Group 84.6% 15.4% 100.0% 
% within Outcome 15.9% 16.7% 16.0% 
% of Total 13.6% 2.5% 16.0% 
Total 
Count 69 12 81 
% within Age Group 85.2% 14.8% 100.0% 
% within Outcome 100.0% 100.0% 100.0% 
% of Total 85.2% 14.8% 100.0% 
 
 
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 0.787a 2 0.675 
Likelihood Ratio 0.793 2 0.673 
Linear-by-Linear Association 0.271 1 0.603 
N of Valid Cases 81   
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AGE VS OUTCOME 
 
2= 0. 787     P= 0.675 
 
 There is no statistical difference in labour outcome between different 
age groups.  
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BMI Classification Vs Outcome 
Crosstab 
 
Outcome 
Term Pre -term Total 
BMI 
Classification 
1 
Count 3 2 5 
% within BMI 
Classification 60.0% 40.0% 100.0% 
% within Outcome 4.3% 16.7% 6.2% 
% of Total 3.7% 2.5% 6.2% 
2 
Count 25 4 29 
% within BMI 
Classification 86.2% 13.8% 100.0% 
% within Outcome 36.2% 33.3% 35.8% 
% of Total 30.9% 4.9% 35.8% 
3 
Count 32 4 36 
% within BMI 
Classification 88.9% 11.1% 100.0% 
% within Outcome 46.4% 33.3% 44.4% 
% of Total 39.5% 4.9% 44.4% 
4 
Count 9 2 11 
% within BMI 
Classification 81.8% 18.2% 100.0% 
% within Outcome 13.0% 16.7% 13.6% 
% of Total 11.1% 2.5% 13.6% 
Total 
Count 69 12 81 
% within BMI 
Classification 85.2% 14.8% 100.0% 
% within Outcome 100.0% 100.0% 100.0% 
% of Total 85.2% 14.8% 100.0% 
 
 
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 3.027a 3 0.387 
Likelihood Ratio 2.410 3 0.492 
Linear-by-Linear Association 0.533 1 0.465 
N of Valid Cases 81   
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BMI CLASSIFICATION VS OUTCOME 
 
2= 3.027    P= 0.562 
There is no statistical difference in labour outcome with respect to BMI. 
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SOCIO ECONOMIC STATUS VS OUTCOME 
Crosstab 
 
Outcome 
Term Pre-term Total 
SE Status 
2 
Count 1 0 1 
% within SE Status 100.0% .0% 100.0% 
% within Outcome 1.4% .0% 1.2% 
% of Total 1.2% .0% 1.2% 
3 
Count 18 1 19 
% within SE Status 94.7% 5.3% 100.0% 
% within Outcome 26.1% 8.3% 23.5% 
% of Total 22.2% 1.2% 23.5% 
4 
Count 36 8 44 
% within SE Status 81.8% 18.2% 100.0% 
% within Outcome 52.2% 66.7% 54.3% 
% of Total 44.4% 9.9% 54.3% 
5 
Count 14 3 17 
% within SE Status 82.4% 17.6% 100.0% 
% within Outcome 20.3% 25.0% 21.0% 
% of Total 17.3% 3.7% 21.0% 
 Total 
Count 69 12 81 
% within SE Status 85.2% 14.8% 100.0% 
% within Outcome 100.0% 100.0% 100.0% 
% of Total 85.2% 14.8% 100.0% 
 
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 2.051a 3 0.562 
Likelihood Ratio 2.553 3 0.466 
Linear-by-Linear Association 1.322 1 0.250 
N of Valid Cases 81   
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SOCIO ECONOMIC STATUS VS OUTCOME 
 
2 =2.051   P=0.562 
 
 There is no significant difference between different socio economic 
status with respect to labour outcome. 
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SOCIO ECONOMIC STATUS VS NEONATAL COMPLICATIONS 
Crosstab 
 
Neonatal Complications 
No complications Respiratory Distress 
Low birth 
weight 
SE 
Status 
2 
Count 1 0 0 
% within Neonatal 
Complications 1.5% .0% .0% 
% of Total 1.2% .0% .0% 
3 
Count 18 1 0 
% within Neonatal 
Complications 27.3% 12.5% .0% 
% of Total 22.2% 1.2% .0% 
4 
Count 35 6 1 
% within Neonatal 
Complications 53.0% 75.0% 100.0% 
% of Total 43.2% 7.4% 1.2% 
5 
Count 12 1 0 
% within Neonatal 
Complications 18.2% 12.5% .0% 
% of Total 14.8% 1.2% .0% 
Total 
Count 66 8 1 
% within Neonatal 
Complications 100.0% 100.0% 100.0% 
% of Total 81.5% 9.9% 1.2% 
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Crosstab 
 
Neonatal Complications 
Jaundice Skin infections Sepsis Total 
SE Status 
2 
Count 0 0 0 1 
% within Neonatal 
Complications .0% .0% .0% 1.2% 
% of Total .0% .0% .0% 1.2% 
3 
Count 0 0 0 19 
% within Neonatal 
Complications .0% .0% .0% 23.5% 
% of Total .0% .0% .0% 23.5% 
4 
Count 2 0 0 44 
% within Neonatal 
Complications 50.0% .0% .0% 54.3% 
% of Total 2.5% .0% .0% 54.3% 
5 
Count 2 1 1 17 
% within Neonatal 
Complications 50.0% 100.0% 100.0% 21.0% 
% of Total 2.5% 1.2% 1.2% 21.0% 
Total 
Count 4 1 1 81 
% within Neonatal 
Complications 100.0% 100.0% 100.0% 100.0% 
% of Total 4.9% 1.2% 1.2% 100.0% 
 
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 13.108a 15 0.594 
Likelihood Ratio 12.890 15 0.611 
Linear-by-Linear Association 7.121 1 0.008 
N of Valid Cases 81   
 
  
46 
 
 
SOCIOECONOMIC STATUS VS NEONATAL COMPLICATIONS 
 
2 =13.108   P=0.594 
 There is no significant difference between different socio economic 
status with respect to neonatal complications.  
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WORKING/NOTWORKING VS OUTCOME 
Crosstab 
 
Outcome 
Term Pre-term Total 
Working/       
Not working 
0 
Count 42 9 51 
% within Working /  
Not working 82.4% 17.6% 100.0% 
% within Outcome 60.9% 75.0% 63.0% 
% of Total 51.9% 11.1% 63.0% 
1 
Count 27 3 30 
% within Working /  
Not working 90.0% 10.0% 100.0% 
% within Outcome 39.1% 25.0% 37.0% 
% of Total 33.3% 3.7% 37.0% 
 Total 
Count 69 12 81 
% within Working /  
Not working 85.2% 14.8% 100.0% 
% within Outcome 100.0% 100.0% 100.0% 
% of Total 85.2% 14.8% 100.0% 
 
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 0.875a 1 0.350   
Continuity Correctionb 0.374 1 0.541   
Likelihood Ratio 0.919 1 0.338   
Fisher's Exact Test    0.520 0.276 
Linear-by-Linear 
Association 0.864 1 0.352   
N of Valid Cases 81     
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WORKING/NOTWORKING VS OUTCOME 
 
2 =0.875    P=0.350 
There is no significant difference between different working status with 
respect to labour outcome. 
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WORKING/NOTWORKING VS NEONATAL COMPLICATIONS 
Crosstab 
 
Neonatal Complications 
No 
complications 
Respiratory 
Distress 
Working/   Not 
working 
Not 
working 
Count 41 6 
% within Neonatal 
Complications 62.1% 75.0% 
% of Total 50.6% 7.4% 
Working 
Count 25 2 
% within Neonatal 
Complications 37.9% 25.0% 
% of Total 30.9% 2.5% 
 Total 
Count 66 8 
% within Neonatal 
Complications 100.0% 100.0% 
% of Total 81.5% 9.9% 
 
Crosstab 
 
Neonatal Complications 
Low birth 
weight Jaundice 
Working/Not 
working 
Not 
working 
Count 0 3 
% within Neonatal 
Complications .0% 75.0% 
% of Total .0% 3.7% 
Working 
Count 1 1 
% within Neonatal 
Complications 100.0% 25.0% 
% of Total 1.2% 1.2% 
 Total 
Count 1 4 
% within Neonatal 
Complications 100.0% 100.0% 
% of Total 1.2% 4.9% 
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Crosstab 
   Neonatal Complications 
   Skin 
infections Sepsis Total 
Working/
Not 
working 
Not 
working 
Count 0 1 51 
% within Neonatal 
Complications 
0.0% 100.0% 63.0% 
% of Total 0.0% 1.2% 63.0% 
Working Count 1 0 30 
% within Neonatal 
Complications 
100.0% 0.0% 37.0% 
% of Total 1.2% 0.0% 37.0% 
 Total Count 1 1 81 
% within Neonatal 
Complications 
100.0% 100.0% 100.0% 
% of Total 1.2% 1.2% 100.0% 
 
 
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 4.754a 5 .447 
Likelihood Ratio 5.709 5 .336 
Linear-by-Linear Association .013 1 .910 
N of Valid Cases 81   
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WORKING/ NOT WORKING VS NEONATAL COMPLICATIONS 
 
2 =4.754   P=0.447 
 
 There is no significant difference between working status with respect 
to neonatal complications. 
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INCLUSION CRITERIA VS OUTCOME 
CROSS TAB 
 
   
Outcome 
Term Preterm Total 
Inclusion 
Criteria 
Abortion 
between 24-
28 Weeks 
Count 30 1 31 
% within Outcome 43.5% 8.3% 38.3% 
% of Total 37.0% 1.2% 38.3% 
Preterm 
Labor 
Count 24 7 31 
% within Outcome 34.8% 58.3% 38.3% 
% of Total 29.6% 8.6% 38.3% 
 
PPROM 
Count 15 4 19 
% within Outcome 21.7% 33.3% 23.5% 
% of Total 18.5% 4.9% 23.5% 
  Total 
Count 69 12 81 
% within Outcome 100% 100% 100% 
% of Total 85.2% 14.8% 100% 
 
 
Chi-Square Tests 
 
 Value Df Asymp.Sig        (2-Sided) 
Pearson Chi-Square 5.366a 2 0.068 
Likelihood Ratio 6.446 2 0.040 
Linear-by-Linear Association 3.705 1 0.054 
N of Valid Cases 81   
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INCLUSION CRITERIA VS OUTCOME 
 
2 =5.366   P=0.068 
 
 There is no significant difference between the different inclusion 
criteria with respect to labour outcome. 
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INCLUSION CRITERIA VS NEONATAL COMPLICATIONS 
 
Crosstab 
Inclusion criteria 
Neonatal Complications 
No 
complications 
Respiratory 
Distress 
Abortion 
between 24-28 
Weeks 
Count 28 0 
% within Neonatal Complications 42.4% 0.0% 
% of Total 34.6% 0.0% 
Preterm labor 
Count 26 4 
% within Neonatal Complications 39.4% 50.0% 
% of Total 32.1% 4.9% 
PPROM 
Count 12 4 
% within Neonatal Complications 18.2% 50.0% 
% of Total 14.8% 4.9% 
Total 
Count 66 8 
% within Neonatal Complications 100.0% 100.0% 
% of Total 81.5% 9.9% 
 
 
Crosstab 
Inclusion criteria 
Neonatal Complications 
Low birth weight Jaundice 
Abortion 
between 24-28 
wks 
Count 0 3 
% within Neonatal Complications 0.0% 75.0% 
% of Total 0.0% 3.7% 
Preterm labor 
Count 0 1 
% within Neonatal Complications 0.0% 25.0% 
% of Total 0.0% 1.2% 
PPROM 
Count 1 0 
% within Neonatal Complications 100.0% .0% 
% of Total 1.2% .0% 
Total 
Count 1 4 
% within Neonatal Complications 100.0% 100.0% 
% of Total 1.2% 4.9% 
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Crosstab 
Inclusion criteria 
Neonatal Complications 
Skin infections Sepsis 
Abortion between 
24-28 Weeks 
Count 0 0 
% within Neonatal Complications 0.0% 0.0% 
% of Total 0.0% 0.0% 
Preterm labor 
Count 0 0 
% within Neonatal Complications 0.0% 0.0% 
% of Total 0.0% 0.0% 
PPROM 
Count 1 1 
% within Neonatal Complications 100.0% 100.0% 
% of Total 1.2% 1.2% 
Total 
Count 1 1 
% within Neonatal Complications 100.0% 100.0% 
% of Total 1.2% 1.2% 
 
Crosstab 
Inclusion criteria Total 
Abortion between 24-28 
Weeks 
Count 31 
% within Neonatal Complications 38.3% 
% of Total 38.3% 
Preterm labor 
Count 31 
% within Neonatal Complications 38.3% 
% of Total 38.3% 
PPROM 
Count 19 
% within Neonatal Complications 23.5% 
% of Total 23.5% 
Total 
Count 81 
% within Neonatal Complications 100.0% 
% of Total 100.0% 
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Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 19.176a 10 .038 
Likelihood Ratio 21.236 10 .020 
Linear-by-Linear Association 2.413 1 .120 
N of Valid Cases 81   
 
INCLUSION CRITERIA VS NEONATAL COMPLICATIONS 
 
2 =19.176   P=0.038 
 
 There exists a statistical significance between various inclusion 
criteria such as abortion, preterm and PPROM with respect to various 
neonatal complications. 
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PASSIVE SMOKING VS OUTCOME 
(H/O Smoking among family members Vs Outcome) 
Cross Tab 
   
Outcome 
Term Preterm Total 
 
H/O 
Smoking 
among 
family 
members 
No Passive 
Smoking 
Count 45 4 49 
% within Outcome 65.2% 33.3% 60.5% 
% of Total 55.6% 4.9% 60.5% 
Passive 
Smoking 
Count 24 8 32 
% within Outcome 34.8% 66.7% 39.5% 
% of Total 29.6% 9.9% 39.5% 
 Total 
Count 69 12 81 
% within Outcome 100% 100% 100% 
% of Total 85.2% 14.8% 100% 
 
Chi-Square Tests 
 Value Df Asymp.Sig        (2-Sided) 
Exact 
Sig. 
(2-Sided) 
Exact Sig. 
(1-Sided) 
Pearson Chi-Square 4.348a 1 0.037   
Continuity 
Correctionb 3.116 1 0.078   
Likelihood Ratio 4.258 1 0.039   
Fisher’s Exact Test    0.054 0.040 
Linear-by-Linear 
Association 4.295 1 0.038   
N of Valid Cases 81     
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PASSIVE SMOKING VS OUTCOME 
 
 
2 =4.348   P=0.037 
 
 Passive smoking increases the risk of preterm labor, which is 
statistically significant. 
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NICU ADMISSION VS OUTCOME 
Cross Tab 
   
Outcome 
Term Preterm Total 
 
 
NICU 
Admission 
No NICU 
Admission 
Count 64 1 65 
% within Outcome 92.8% 8.3% 80.2% 
% of Total 79.0% 1.2% 80.2% 
NICU 
Admission 
Count 5 11 16 
% within Outcome 7.2% 91.7% 19.8% 
% of Total 6.2% 13.6% 19.8% 
 Total 
Count 69 12 81 
% within Outcome 100% 100% 100% 
% of Total 85.2% 14.8% 100% 
 
Chi-Square Tests 
 Value Df Asymp.Sig        (2-Sided) 
Exact 
Sig. 
(2-Sided) 
Exact 
Sig. 
(1-Sided) 
Pearson Chi-
Square 45.960
a 1 0.000   
Continuity 
Correctionb 40.788 1 0.000   
Likelihood Ratio 37.748 1 0.000   
Fisher’s Exact 
Test    0.000  
Linear-by-Linear 
Association 45.392 1 0.000   
N of Valid Cases 81     
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NICU ADMISSION VS OUTCOME 
 
2 =45.960   P=0.000 
 
 There exists a statistical significant increase in the risk of NICU 
admissions with respect to preterm labor. 
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NICU ADMISSION VS NEONATAL COMPLICATIONS 
Crosstab 
   Neonatal Complications 
   No complications 
Respiratory 
Distress 
 
 
 
 
NICU 
Admission 
No NICU  
admission 
Count 65 0 
% within Neonatal 
Complications 98.5% .0% 
% of Total 80.2% .0% 
NICU 
admission 
Count 1 8 
% within Neonatal 
Complications 1.5% 100.0% 
% of Total 1.2% 9.9% 
 Total 
Count 66 8 
% within Neonatal 
Complications 100.0% 100.0% 
% of Total 81.5% 9.9% 
 
Crosstab 
   Neonatal Complications 
   Low birth weight Jaundice 
NICU 
Admission 
No NICU  
admission 
Count 0 0 
% within Neonatal 
Complications 0.0% 0.0% 
% of Total 0.0% 0.0% 
NICU 
admission 
Count 1 4 
% within Neonatal 
Complications 100.0% 100.0% 
% of Total 1.2% 4.9% 
 
 
 
Total 
Count 1 4 
% within Neonatal 
Complications 100.0% 100.0% 
% of Total 1.2% 4.9% 
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Crosstab 
   Neonatal Complications 
   Skin infections Sepsis 
 
 
 
NICU 
Admission 
No NICU  
admission 
Count 0 0 
% within Neonatal 
Complications 0.0% 0.0% 
% of Total 0.0% 0.0% 
NICU 
admission 
Count 1 1 
% within Neonatal 
Complications 100.0% 100.0% 
% of Total 1.2% 1.2% 
 Total 
Count 1 1 
% within Neonatal 
Complications 100.0% 100.0% 
% of Total 1.2% 1.2% 
 
 
Crosstab 
   Total 
NICU 
Admission 
No NICU  admission 
Count 65 
% within Neonatal 
Complications 80.2% 
% of Total 80.2% 
NICU admission 
Count 16 
% within Neonatal 
Complications 19.8% 
% of Total 19.8% 
 Total 
Count 81 
% within Neonatal 
Complications 100.0% 
% of Total 100.0% 
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Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 74.787a 5 .000 
Likelihood Ratio 70.143 5 .000 
Linear-by-Linear Association 49.988 1 .000 
N of Valid Cases 81   
 
NICU ADMISSION VS NEONATAL COMPLICATIONS 
 
2 =74.787   P=0.000 
 There exists a statistically significant increase in neonatal 
complications in neonates admitted to NICU. 
  
64 
 
NEONATAL MORTALITY VS OUTCOME 
Cross Tab 
   
Outcome 
Term Preterm Total 
 
 
Neonatal 
Mortality 
 
0 
Count 69 11 80 
% within Outcome 100.0% 91.7% 98.8% 
% of Total 85.2% 13.6% 98.8% 
1 
Count 0 1 1 
% within Outcome 0.0% 8.3% 1.2% 
% of Total 0.0% 1.2% 1.2% 
  Total 
Count 69 12 81 
% within Outcome 100% 100% 100% 
% of Total 85.2% 14.8% 100% 
 
Chi-Square Tests 
 
  
 Value Df Asymp.Sig        (2-Sided) 
Exact Sig. 
(2-Sided) 
Exact Sig. 
(1-Sided) 
Pearson Chi-Square 5.822a 1 0.016   
Continuity Correctionb 0.993 1 0.319   
Likelihood Ratio 3.892 1 0.049   
Fisher’s Exact Test    0.148 0.148 
Linear-by-Linear 
Association 5.750 1 0.016   
N of Valid Cases 81     
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NEONATAL MORTALITY VS OUTCOME 
 
2=5.822   P=0.016 
 
Neonatal mortality is increased in the preterm group which is 
statistically significant. 
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NEONATAL MORTALITY VS NEONATAL COMPLICATIONS 
Crosstab 
   Neonatal Complications 
   No complications 
Respiratory 
Distress 
Low 
birth 
weight 
Neonatal 
Mortality 
 
 
0 
Count 66 7 1 
% within Neonatal 
Complications 100.0% 87.5% 100.0% 
% of Total 81.5% 8.6% 1.2% 
 
 
1 
Count 0 1 0 
% within Neonatal 
Complications .0% 12.5% .0% 
% of Total .0% 1.2% .0% 
  Total 
Count 66 8 1 
% within Neonatal 
Complications 100.0% 100.0% 100.0% 
% of Total 81.5% 9.9% 1.2% 
 
Crosstab 
   Neonatal Complications 
   Jaundice Skin infections Sepsis Total 
Neonatal 
Mortality 
 
0 
Count 4 1 1 80 
% within 
Neonatal 
Complications 
100.0% 100.0% 100.0% 98.8% 
% of Total 4.9% 1.2% 1.2% 98.8% 
 
1 
Count 0 0 0 1 
% within 
Neonatal 
Complications 
0.0% 0.0% 0.0% 1.2% 
% of Total 0.0% 0.0% 0.0% 1.2% 
  Total 
Count 4 1 1 81 
% within 
Neonatal 
Complications 
100.0% 100.0% 100.0% 100.0% 
% of Total 4.9% 1.2% 1.2% 100.0% 
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Chi-Square Tests 
 Value Df Asymp. Sig.  (2-sided) 
Pearson Chi-Square 9.239a 5 0.100 
Likelihood Ratio 4.748 5 0.447 
Linear-by-Linear Association .400 1 0.527 
N of Valid Cases 81   
 
NEONATAL MORTALITY VS NEONATAL COMPLICATIONS 
 
2 =9.239  P=0.1000 
 
 There is no significant difference between neonatal mortality with 
respect to various neonatal complications. 
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GROUP STATISTICS AND INDEPENDENT SAMPLE TEST 
BIOMARKER VS OUTCOME 
 
Group Statistics 
 Outcome N Mean Std. Deviation 
Std. Error 
Mean 
Progesterone 24 to 
28 Weeks 
Pre-term 12 3271.67 350.201 101.094 
Term 69 4391.70 315.002 37.922 
Progesterone 29to 
32 Weeks 
Pre-term 12 2625.75 220.241 63.578 
Term 69 3735.52 272.550 32.811 
 
Independent Samples Test 
  Levene's Test for Equality of Variances 
t-test for 
Equality 
of Means 
  F Sig. T 
Progesterone 24 
to 28 Weeks 
Equal variances assumed 0.003 0.954 -11.186 
Equal variances not 
assumed   -10.373 
Progesterone 29 
to 32 Weeks 
Equal variances assumed 0.822 0.367 -13.345 
Equal variances not 
assumed   -15.511 
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Independent Samples Test 
  t-test for Equality of Means 
   95% Confidence Interval of the Difference 
  Std. Error Difference Lower Upper 
Progesterone 24 to 
28 weeks 
Equal variances 
assumed 100.129 -1319.331 -920.727 
Equal variances not 
assumed 107.973 -1351.201 -888.857 
Progesterone 29to 
32 Weeks 
Equal variances 
assumed 83.161 -1275.299 -944.244 
Equal variances not 
assumed 71.545 -1260.430 -959.113 
 
Progesterone 24-28 Weeks t = -11.186 P =0.000 
Progesterone 29-32 Weeks t = -13.345 P =0.000 
  
 There is a statistical significance existing between labor outcome with 
respect to progesterone level between 24 to 28 weeks and 29 to 32 
weeks.i.e., lower the progesterone level, higher the incidence of preterm 
labor. 
Independent Samples Test 
  t-test for Equality of Means 
  df Sig. (2-tailed) 
Mean 
Difference 
Progesterone  
24 to 28 Weeks 
Equal variances assumed 79 0.000 -1120.029 
Equal variances not assumed 14.268 0.000 -1120.029 
Progesterone 29to 32 
Weeks 
Equal variances assumed 79 0.000 -1109.772 
Equal variances not assumed 17.440 0.000 -1109.772 
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BIOMARKER VS NEONATAL COMPLICATIONS 
Group Statistics 
 Neonatal Complications N Mean 
Progesterone 24 to 28 
Weeks 
Neonatal complications 15 3608.93 
No complications 66 4365.95 
Progesterone 29to 32 
Weeks 
Neonatal complications 15 3000.27 
No complications 66 3700.85 
 
 
Group Statistics 
 Neonatal Complications Std. Deviation Std. Error Mean 
Progesterone 24 
to 28 Weeks 
Neonatal complications 626.924 161.871 
No complications 359.766 44.284 
Progesterone 29to 
32 Weeks 
Neonatal complications 646.492 166.923 
No complications 311.924 38.395 
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Independent Samples Test 
  Levene's Test for Equality of Variances 
t-test for 
Equality of 
Means 
  F Sig. t 
Progesterone 24 
to 28 Weeks 
Equal variances assumed 13.355 0.000 -6.306 
Equal variances not 
assumed   -4.511 
Progesterone 29to 
32 Weeks 
Equal variances assumed 27.593 0.000 -6.239 
Equal variances not 
assumed   -4.090 
 
 
Independent Samples Test 
  t-test for Equality of Means 
  df Sig. (2-tailed) 
Mean 
Difference 
Progesterone 24 
to 28 Weeks 
Equal variances assumed 79 0.000 -757.021 
Equal variances not 
assumed 16.155 0.000 -757.021 
Progesterone 
29to 32 Weeks 
Equal variances assumed 79 0.000 -700.582 
Equal variances not 
assumed 15.511 0.001 -700.582 
 
 
72 
 
Independent Samples Test 
  t-test for Equality of Means 
   
95% Confidence 
Interval of the 
Difference 
  Std. Error Difference Lower Upper 
Progesterone 24 
to 28 Weeks 
Equal variances 
assumed 120.050 -995.974 -518.068 
Equal variances not 
assumed 167.819 -1112.506 -401.537 
Progesterone 29to 
32 Weeks 
Equal variances 
assumed 112.294 -924.098 -477.066 
Equal variances not 
assumed 171.282 -1064.616 -336.547 
 
Progesterone 24-28 Weeks t = -6.306 P =0.000 
Progesterone 29-32 Weeks t = -6.239 P =0.000 
 
 There is a statistical significance existing between neonatal 
complications and progesterone level between 24 to 28 weeks and 29 to 32 
weeks .i.e., lower the progesterone level , greater the neonatal 
complications. 
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CERVIX LENGTH VS OUTCOME 
Group Statistics 
 Outcome N Mean Std. Deviation 
Std. Error 
Mean 
cx 24 to 28 Weeks 
Pre term 12 2.917 0.1946 0.0562 
Term 69 3.555 0.2373 0.0286 
cx 29 to 32 Weeks 
Pre term 12 2.592 0.1379 0.0398 
Term 69 3.442 0.2366 0.0285 
 
Independent Samples Test 
  
Levene's Test for 
Equality of 
Variances 
t-test for Equality 
of Means 
  F Sig. T Df 
cx 24 to 28 
wks 
Equal variances 
assumed 1.673 .200 -8.803 79 
Equal variances not 
assumed   -10.128 17.240 
cx 29 to 32 
wks 
Equal variances 
assumed 4.723 .033 -12.057 79 
Equal variances not 
assumed   -17.372 24.130 
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Cervix length 24-28 Weeks t = -5.899 P =0.000 
Cervix length 29-32 Weeks t = -6.457 P =0.000 
 
 There is a statistical significant increase in the risk of preterm labor 
with respect to decrease in cervix length between 24 to 28 weeks and 29 to 
32 weeks. 
  
Independent Samples Test 
  t-test for Equality of Means 
  95% Confidence Interval of the Difference 
  Lower Upper 
cx 24 to 
28 weeks 
Equal variances assumed -0.7828 -0.4941 
Equal variances not assumed -0.7713 -0.5056 
cx 29 to 
32 weeks 
Equal variances assumed -0.9908 -0.7100 
Equal variances not assumed -0.9514 -0.7494 
Independent Samples Test 
  t-test for Equality of Means 
  Sig.          (2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
cx 24 to 28 
wks 
Equal variances 
assumed .000 -.6384 .0725 
Equal variances not 
assumed .000 -.6384 .0630 
cx 29 to 32 
wks 
Equal variances 
assumed .000 -.8504 .0705 
Equal variances not 
assumed .000 -.8504 .0490 
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CERVIX LENGTH VS NEONATAL COMPLICATIONS 
Group Statistics 
 Neonatal Complications N Mean 
Std. 
Deviation 
Std. Error 
Mean 
cx 24 to 28 
weeks 
Neonatal 
complications 15 3.087 0.3091 0.0798 
No complications 66 3.545 0.2632 0.0324 
cx 29 to 32 
weeks 
Neonatal 
complications 15 2.853 0.4121 0.1064 
No complications 66 3.421 0.2798 0.0344 
 
 
Independent Samples Test 
  
Levene's Test for 
Equality of 
Variances 
t-test for Equality 
of Means 
  F Sig. t Df 
cx 24 to 28 
weeks 
Equal variances 
assumed 1.469 0.229 -5.899 79 
Equal variances not 
assumed   -5.327 18.886 
cx 29 to 32 
weeks 
Equal variances 
assumed 8.930 0.004 -6.457 79 
Equal variances not 
assumed   -5.078 17.048 
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Independent Samples Test 
  t-test for Equality of Means 
  Sig.          (2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
cx 24 to 28 
weeks 
Equal variances 
assumed 0.000 -0.4588 0.0778 
Equal variances not 
assumed 0.000 -0.4588 0.0861 
cx 29 to 32 
weeks 
Equal variances 
assumed 0.000 -0.5679 0.0879 
Equal variances not 
assumed 0.000 -0.5679 0.1118 
 
Independent Samples Test 
  t-test for Equality of Means 
  95% Confidence Interval of the Difference 
  Lower Upper 
cx 24 to 28 
weeks 
Equal variances assumed -0.6136 -0.3040 
Equal variances not 
assumed -0.6391 -0.2784 
cx 29 to 32 
weeks 
Equal variances assumed -0.7429 -0.3928 
Equal variances not 
assumed -0.8038 -0.3320 
 
Cervix length 24-28 Weeks t = -8.803 P =0.000 
Cervix length 29-32 Weeks t = -12.057 P =0.000 
 
 There is a statistical significant increase in the risk of  neonatal 
complications with decreasing  cervix length between 24 to 28 weeks and 
29 to 32 weeks. 
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CORRELATION 
 
BMI VS BIOMARKER/CERVIX LENGTH 
 
BMI 
Progesterone 
24-28 weeks 
Progesterone 29-
32 weeks 
Cervix length 
24-28 weeks 
Cervix length 
29-32 weeks 
t = - 0.103 t = - 0.031 t = - 0.071 t = - 0.018 
P = 0.361 P = 0.785 P = 0.530 P = 0.875 
Not Significant Not Significant Not Significant Not Significant 
 
 There is no statistical significance existing between BMI and 
pregnancyoutcome – term/preterm. 
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 HEIGHT, WEIGHT, BMI VS OUTCOME 
Group Statistics 
 Outcome N Mean Std. Deviation 
Std. Error 
Mean 
Height 
Pre-term 12 153.92 5.534 1.598 
Term 69 155.04 5.574 .671 
Weight 
Pre-term 12 54.42 11.912 3.439 
Term 69 57.87 10.492 1.263 
BMI 
Pre-term 12 23.01 4.874 1.407 
Term 69 24.11 3.976 .479 
 
Independent Samples Test 
  Levene's Test for Equality of Variances 
t-test for Equality of 
Means 
  F Sig. T df 
Height 
Equal variances 
assumed 0.204 0.653 -0.647 79 
Equal variances not 
assumed   -0.650 15.148 
Weight 
Equal variances 
assumed 1.095 0.299 -1.032 79 
Equal variances not 
assumed   -0.943 14.127 
BMI 
Equal variances 
assumed 2.193 0.143 -0.854 79 
Equal variances not 
assumed   -0.739 13.663 
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Independent Samples Test 
  t-test for Equality of Means 
  Sig. (2-tailed) Mean Difference 
Std. Error 
Difference 
Height 
Equal variances assumed 0.520 -1.127 1.742 
Equal variances not 
assumed 0.525 -1.127 1.733 
Weight 
Equal variances assumed 0.305 -3.453 3.347 
Equal variances not 
assumed 0.362 -3.453 3.663 
BMI 
Equal variances assumed 0.396 -1.099 1.286 
Equal variances not 
assumed 0.472 -1.099 1.486 
 
 
 
Independent Samples Test 
  t-test for Equality of Means 
  95% Confidence Interval of the Difference 
  Lower Upper 
Height 
Equal variances 
assumed -4.594 2.340 
Equal variances not 
assumed -4.817 2.564 
Weight 
Equal variances 
assumed -10.115 3.209 
Equal variances not 
assumed -11.304 4.398 
BMI 
Equal variances 
assumed -3.659 1.461 
Equal variances not 
assumed -4.294 2.096 
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Height Weight BMI 
t = - 0.647 t = - 1.032 t = - 0.854 
P = 0.520 P = 0.305 P = 0.396 
Not Significant Not Significant Not Significant 
 
 There is no statistical significance existing between height, weight 
and BMI with respect to pregnancy outcome – term/preterm.  
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HEIGHT, WEIGHT, BMI VS NEONATAL COMPLICATIONS 
Group Statistics 
 Neonatal Complications N Mean 
Std. 
Deviation 
Std. Error 
Mean 
Height 
Neonatal 
complications 15 154.13 6.707 1.732 
No 
complications 66 155.05 5.296 .652 
Weight 
Neonatal 
complications    2.388 
No 
complications 66 58.26 10.872 1.338 
BMI 
Neonatal 
complications 15 22.593 4.0383 1.0427 
No 
complications 66 24.252 4.0886 .5033 
  
Independent Samples Test 
  Levene's Test for Equality of Variances 
t-test for Equality of 
Means 
  F Sig. t Df 
Height 
Equal variances 
assumed 1.506 0.223 -0.572 79 
Equal variances not 
assumed   -0.493 18.170 
Weight 
Equal variances 
assumed 0.083 0.774 -1.602 79 
Equal variances not 
assumed   -1.774 23.670 
BMI 
Equal variances 
assumed .126 .724 -1.421 79 
Equal variances not 
assumed   -1.432 21.037 
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Independent Samples Test 
  t-test for Equality of Means 
  Sig.          (2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
Height 
Equal variances 
assumed 0.569 -0.912 1.594 
Equal variances not 
assumed 0.628 -0.912 1.850 
Weight 
Equal variances 
assumed 0.113 -4.858 3.033 
Equal variances not 
assumed 0.089 -4.858 2.737 
BMI 
Equal variances 
assumed 0.159 -1.6582 1.1670 
Equal variances not 
assumed 0.167 -1.6582 1.1578 
 
Independent Samples Test 
  t-test for Equality of Means 
  95% Confidence Interval of the Difference 
  Lower Upper 
Height 
Equal variances assumed -4.084 2.260 
Equal variances not 
assumed -4.797 2.973 
Weight 
Equal variances assumed -10.894 1.179 
Equal variances not 
assumed -10.512 .796 
BMI 
Equal variances assumed -3.9810 .6646 
Equal variances not 
assumed -4.0657 .7493 
 
83 
 
 
 
Height Weight BMI 
t = - 0.572 t = - 1.602 t = - 1.421 
P = 0.569 P = 0.113 P = 0.159 
Not Significant Not Significant Not Significant 
 
 There is no statistical significance existing between height, weight 
and BMI with respect to neonatal complications. 
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LOGISTIC REGRESSION 
 
Dependent Y GA_at_delivery 
Independent X progesterone_24_to_28_wks progesterone 24 to 28 wks 
Sample size 81 
Coefficient of determination R2 0.5486 
Residual standard deviation 1.2407 
 
 
Regression Equation 
 
y = 26.1645  +  0.002658  x 
Parameter Coefficient Std. Error 95% CI t P 
Intercept 26.1645 1.1545 23.8665  - 28.4625 22.6629 <0.0001 
Slope 0.002658 0.0002713 0.002118 - 0.003198 9.7977 <0.0001 
 
 
Analysis of Variance 
 
Source DF Sum of Squares Mean Square 
Regression 1 147.7583 147.7583 
Residual 79 121.5998 1.5392 
 
  
F-ratio 95.9945 
Significance level P<0.001 
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LOGISTIC REGRESSION 
 
Dependent Y GA_at_delivery 
Independent X progesterone_29to_32_wks progesterone 29to 32 wks 
Sample size 81 
Coefficient of determination R2 0.5763 
Residual standard deviation 1.2019 
 
 
 Regression Equation 
 
y = 26.9582  +  0.002923  x 
Parameter Coefficient Std. Error 95% CI T P 
Intercept 26.9582 1.0156 24.9367 - 28.9797 26.5437 <0.0001 
Slope 0.002923 0.0002819 0.002361- 0.003484 10.3664 <0.0001 
 
 
Analysis of Variance 
 
Source DF Sum of Squares Mean Square 
Regression 1 155.2374 155.2374 
Residual 79 114.1206 1.4446 
 
 
 
 The scatter diagram shows that there exists a linear relationship between 
salivary progesterone level and cervix length with respect to labor outcome. 
F-ratio 107.4631 
Significance level P<0.001 
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Discussion 
  
87 
 
DISCUSSION 
  
 A total of 90 women were enrolled in our study. Two women were 
diagnosed to have Hyperglycemia in pregnancy between 29-32 weeks and 
were excluded from the study. Three women developed hypertensive 
disorder of pregnancy and were excluded from the study. One woman was 
diagnosed by USG to have fetal growth restriction with oligohydramnios 
and was excluded from the study. Three women did not turn up between  
29-32 weeks of gestation due to various reasons and were excluded from the 
study. 
 
 The study analyzed the values of salivary progesterone estimation as 
a   predictor of preterm birth. Salivary progesterone levels were compared 
with transvaginal cervical length during the same gestational age. Other 
variables-socioeconomic status, working status, height, weight, body mass 
index, passive smoking, neonatal complications and neonatal mortality were 
also analyzed. 
 
 ROC curve was drawn for salivary progesterone between 24-28 weeks 
and 29-32 weeks with respect to term and preterm deliveries. Sensitivity 
and specificity of salivary progesterone in predicting preterm labor, 
when done between 24-28 weeks was 100% and 94.2% respectively, 
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when the criterion was set as ≤3903pg/ml. The same when repeated 
between 29-32 weeks, sensitivity and specificity was 100% and 100% 
respectively when the criterion was set as ≤2975pg/ml. 
 Similarly, ROC curve was drawn for transvaginal cervical length 
between 24-28 weeks and 29-32 weeks with respect to term and preterm 
deliveries. Sensitivity and specificity of transvaginal cervical length in 
predicting preterm labor was 91.7% and 95.7% respectively at 24-28 
weeks when the criterion was set as ≤ 3.1cm and 100% and 98.6% 
respectively, when done at 29-32 weeks, and the criterion  set as ≤ 
2.9cm. 
 The sensitivity and specificity for both salivary progesterone and  
transvaginal cervical length  in prediction of preterm labor were greater 
when done at a later gestational age.  
 ROC curve was drawn for salivary progesterone between 24-28 weeks 
and 29-32 weeks with respect to neonatal complications. Sensitivity and 
specificity were 100% and 93.9% respectively when done between 24-28 
weeks and criterion set as ≤3703pg/ml. Sensitivity and specificity were 
100% and 98.5% respectively when done between 29-32 weeks and 
criterion set as ≤2935pg/ml. 
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 ROC curve was drawn for transvaginal cervix length between 24-28 
weeks and 29-32 weeks with respect to neonatal complications. 
Sensitivity and specificity were 100% and 93.9% respectively when done 
between 24-28 weeks and criterion set as ≤3.1cm. Sensitivity and 
specificity were 100% and 97%, when done between 29-32 weeks and 
criterion set as ≤2.7cm. 
 The relation of age with respect to labor outcome describes the chi-
square =0.787 and P=0.675 which is not significant. Thus age did not 
have any impact on labor outcome. 
 The relation of BMI with respect to labor outcome describes the chi-
square= 3.027 and P = 0.387 which is not significant.. Thus BMI did not 
have any impact on labor outcome. 
 The relation of socioeconomic status with respect to preterm labor 
describes the chi square = 2.051 and P = 0.562 which is not significant. 
Thus socioeconomic status did not have any impact on the prediction for 
preterm labor. 
 The relation of socioeconomic status with respect to neonatal 
complications describes the chi square = 13.108 and P = 0.594 which is 
not significant. Thus socioeconomic status did not have any impact on 
neonatal complications. 
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 The relation of women in working group for risk of preterm labor 
describes the chi square = 0.875 and P =0.350 which is not significant. 
Thus women who belonged to the working group did not have a 
predilection for preterm labor. 
 The relation of women in working group for risk of neonatal 
complications describes chi square = 4.754 and P = 0.447 which is not 
significant. Thus women who belonged to the working group did not 
have a predilection for neonatal complications. 
 The relation of different inclusion criteria with respect to preterm labor     
describes the chi square=5.366 and P = 0.068 which is not significant. 
Thus percentage of recurrence of preterm labor does not vary among the 
group with different inclusion criteria. 
 The relation of different inclusion criteria with respect to neonatal 
complications describes the chi square =19.176 and P = 0.038 which is 
significant. Thus the neonatal complications did have a significant 
relationship with history of abortion and preterm group i.e 38.3% with 
preterm labor and abortion group and 23.5%   with PPROM group. 
 The relation of passive smoking with preterm labor describes the chi 
square = 4.348 and P = 0.037 which is significant. There is an increased 
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incidence of preterm labor in group with history of passive smoking i.e 
66.7% in preterm group and 34.8% in term group. 
 The relation of passive smoking with neonatal complications describes 
the chi square = 7.315 and P = 0.198 which is not significant. There is no 
increased incidence of neonatal complications in group with history of 
passive smoking. 
 The relation of NICU admission with respect to pregnancy outcome, 
term/preterm describes the chi square = 45.960 and P = 0.000 which is 
significant. Thus neonates belonging to preterm birth group had higher 
incidence of NICU admissions i.e 13.6% in preterm labor group vs 6.2% 
in term labor group. 
 The relation of NICU admission with respect to neonatal complications 
describes the chi square = 74.787 and P = 0.000 which is significant. 
99% - Respiratory distress syndrome, 4.9% Jaundice, 1.2% Low birth 
weight, 1.2% skin infections, 1.2% sepsis. 
 The relation of neonatal mortality with respect to preterm labor describes 
the chi square = 5.822 and P = 0.016 which is significant. Incidence of 
neonatal mortality is1.2% in the preterm group. 
 The relation of neonatal mortality with respect to neonatal complications 
describes the chi square = 9.239 and P = 0.100 which is not significant.  
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 The t-test showed a good correlation between salivary progesterone and 
transvaginal cervical length with respect to pregnancy outcome and 
neonatal complications as they describe P = 0.000 which is significant. 
i.e., lower the progesterone, higher the incidence of preterm labor and 
neonatal complications. 
 The correlation between BMI with salivary progesterone and cervix 
length between 24 to 28 weeks and 29-32 weeks. (Progesterone 24-28 
weeks- P = 0.361; Progesterone 29-32 weeks- P = 0.785; cervix 24-28 
weeks- P = 0.530; cervix 29-32 weeks- P = 0.875 ) is not significant. 
Thus pre pregnancy BMI had no impact on pregnancy outcome in this 
study. 
 The t-test done for correlating height, weight and BMI with pregnancy 
outcome describes P value (  height- P = 0.520; weight- P = 0.305 and 
BMI- P = 0.396) which is not significant. Height, weight and BMI did 
not have significant impact on pregnancy outcome i.e term or preterm. 
 The t-test done for correlating height, weight and BMI with neonatal 
complications describes P value (height - P = 0.569; Weight -P = 0.113; 
BMI- P = 0.159) which is not significant. Thus height, weight and BMI 
did not have significant impact on neonatal complications. 
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 The logistic regression curve relating salivary progesterone level to 
gestational age at delivery shows a statistically significant linear 
relationship. i.e., lower the salivary progesterone level, lesser is the 
gestational age of delivery. 
 The regression  equation thus derived  i.e., multiplying the estimated 
salivary progesterone level by a constant value and adding another 
constant value for that gestational age, at which salivary progesterone 
level is estimated, gives  the gestational age of delivery. 
Y= 26.1645 + 0.002658 x Salivary progesterone level at 24 to 28 weeks. 
Y = 26.9582 + 0.002923 x Salivary progesterone level at 29 to 32 weeks. 
Where, Y is the gestational age at delivery. 
  
  
Summary 
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SUMMARY 
  
1. The age, pre- pregnancy height, weight and Body mass index was not 
useful in predicting the preterm labor and neonatal complications. 
2.  The risk of preterm labour were not increased in working women.  
3. Socio economic status did not have a significant impact on labor 
outcome and neonatal complications. 
4. The incidence of recurrence of preterm labor did not vary among 
patients with previous history of  spontaneous abortion between 20-28 
weeks, preterm labor and PPROM. 
5. The risk of neonatal complications in women with preterm labor were 
more in those with previous history of spontaneous abortion between 
20-28 weeks and previous history of preterm labor. A similar 
association was not seen in those with previous history of PPROM.  
6. Women with passive smoking (i.e history of smoking among family 
members) were at a greater risk for preterm labor.  
7. Neonates of women with passive smoking were not more prone for 
neonatal complications. 
8. Risk of NICU admissions were more in preterm deliveries. 
9. Most common cause for admission in NICU, in preterm deliveries 
being respiratory distress syndrome followed by jaundice. 
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10. Neonatal mortality is more in preterm deliveries, the prime cause being 
respiratory distress. 
11. Salivary progesterone estimation at 24-28 weeks and then at 29-32 
weeks in asymptomatic high risk AN mothers was a valuable predictor 
of preterm labor when the cut off was fixed at ≤ 3903pg/ml at 24-28 
weeks and ≤ 2975 pg/ml at 29-30 weeks. 
12. Transvaginal cervical length measured at 24-28 weeks and then at 29-
32 weeks, at the time of salivary progesterone estimation also, had 
similar sensitivity and specificity in predicting preterm labor when the 
cut off was fixed at  ≤3.1cm at 24-28 weeks and ≤2.9cm at 29-32 
weeks. 
  
Conclusion 
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CONCLUSION 
 
 Salivary progesterone is a better predictor of preterm labor when 
compared to transvaginal cervical length, as it has better sensitivity and 
specificity, is a non-invasive method and sample collection is easier. 
Though transvaginal scan is available in  every antenatal unit, it needs 
technical expertise and   further , it shows  inter-observer variability. 
 
 An ideal biochemical marker must be able to predict the problem at an 
earlier GA for appropriate interventions to be done. Hence it is justified in 
doing the salivary progesterone estimation at 24-28 weeks though it has 
comparatively lesser sensitivity and specificity than at 29-32 weeks. 
 
 In utero transfer can be advised for antenatal women whose salivary 
progesterone level  are  ≤3903pg/ml at 24-28 weeks and ≤2975pg/ml at 29-
32 weeks for better obstetric outcome and better neonatal salvageability. 
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Annexures 
 
PROFORMA 
 
Name     : 
Age     : 
Address    : 
S.No     : 
Occupation    : 
Height    : 
Weight    : 
Body mass index   : 
Obstetric code   : 
Last menstrual period  : 
Expected date of delivery : 
Socio economic status  : 
Menstrual History   : 
Marital History   : 
Obstetric History   : 
Dating scan done or not  : 
Anomaly scan done or not : 
Past History    :         
H/O abortion/preterm labour/prelabour rupture of membrane. 
DM/HT/Twins/Heart disease/on any drugs. 
TB/epilepsy/renal disease : 
Family History  H/O smoking among family members in her residence 
Personal History    : 
General Examination   : 
Pallor 
Edema 
Vitals      
Temperature                                    : 
Pulse rate                                          :  
Blood pressure                                  : 
Respiratory rate                               :   
Systemic Examination   
Cardiovascular System                    : 
Respiratory System                          : 
Central Nervous System 
Abdominal Examination 
INVESTIGATIONS 
1. Urine - Sugar/Albumin/Microscopy/culture and sensitivity 
2. Complete haemogram 
3. OGCT 
4. Blood Urea 
5. High vaginal swab culture and sensitivity 
6. Dating USG 
7. Anomary USG 
8. Salivary progesterone estimation-twice 1st sample between 24 to 28 
weeks of GA and 2nd 3-4 weeks after 1st sample  
9. Transvaginal cervical length measurement-done along with salivary  
10. progesterone estimation 
    
 Delivered at 
 Gestational age in weeks 
 Mode of delivery 
 NICU Admissions: 
 Birth weight 
 Neonatal morbidity 
 Neonatal morality 
pr
og cx Pr
og cx
1 Amutha 29 4 1 155 75 31.2 G4P2L1A1 2 1 3150 2.7 2748 2.4 33+4 2.24 1 0 1 0
2 Dhana lakshmi 27 5 0 148 45 20.5 G2P1L0 2 1 2942 2.8 2696 2.5 34+2 1.9 1 0 1 1
3 Rukayal 27 4 1 153 60 25.6 G2A1 1 0 4268 3.5 3596 3.5 38+2 2.8 0 0 0 0
4 Kalpana 29 4 0 149 42 18.9 G3P1L1A1 1 0 4751 3.8 4124 3.6 38+6 3.1 0 0 0 0
5 Gomathi 25 5 0 154 49 20.7 G3P1L1A1 2 0 3903 3.4 2975 2.9 36+3 2.46 0 0 1 0
6 Amalu 34 4 0 158 53 21.3 G4P1L1A2 1 0 4223 4 3643 3.8 38+1 2.9 0 0 0 0
7 Renuka 28 3 0 163 50 18.9 G4A3 1 1 4939 3.9 3815 3.7 37+5 3.1 0 0 0 0
8 Sumathi 24 4 0 164 58 21.6 G3P1L1A1 1 1 4779 3.6 4367 3.5 39+1 2.78 0 0 0 0
9 Sufiya 30 4 0 153 63 26.9 G4P1L1A2 2 1 3703 3 2654 2.7 36+2 2.45 1 0 1 1
10 Sameena 29 4 1 159 75 29.6 G4P1L1A2 2 0 4280 3.2 3186 3 38+1 2.4 0 0 0 0
11 Amsa Lekha 29 5 0 160 44 17.2 G3P1L1A1 3 0 4150 3.3 3768 3.3 39+1 2.8 0 0 0 0
12 Meenakshi 31 4 0 159 47 18.6 G3P1L1A1 3 0 3088 2.8 2935 2.6 32+1 1.8 1 0 1 1
13 Prema 32 4 1 142 55 27.5 G4P3L1D2 3 0 4269 3.3 3786 3.2 38 2.45 1 0 0 2
14 Maha lakshmi 32 4 0 149 56 25.5 G3P1L1A1 1 0 4536 3.8 3549 3.6 37+2 2.7 0 0 0 0
15 Sufaija 23 4 0 148 52 23.6 G4A3 1 0 4454 3.9 3987 3.8 40+2 3 0 0 0 0
16 Maria 38 3 0 156 70 29.2 G2P1L1 3 0 3497 3.1 2548 2.6 35+5 2.1 1 0 1 1
17 Selvi 26 4 0 162 68 26.2 G4P1L1A2 3 0 4045 3.6 3216 3.4 38+4 2.65 0 0 0 0
18 Sasi kala 29 3 0 150 50 22.2 G3P2L1A1 2 0 3814 3.5 3418 3.4 37+3 2.55 0 0 0 0
19 Nirmala 28 3 0 153 70 29.9 G2A1 1 0 3476 3.5 3212 3.5 38+3 2.64 0 0 0 0
20 Sudha 23 4 1 155 58 24.2 G4P1L1A2 3 1 2554 2.7 2292 2.6 31+2 1.5 1 1 1 1
21 Rangeela 22 5 0 151 48 21 G2A1 1 0 4931 4 3775 3.8 39+5 3.2 0 0 0 0
22 Vallithai 27 4 0 148 62 28.2 G4P1L1A2 1 1 4280 3.5 3668 3.2 39 2.54 0 0 0 0
23 Sathya 28 4 0 154 65 27.4 G3P1L1A1 3 0 3156 2.9 2549 2.5 33+3 1.75 1 0 1 1
24 Sameeja 24 3 1 159 55 21.8 G2A1 1 1 4635 3.8 3814 3.6 38+3 3 0 0 0 0
25 Nisha 18 5 0 150 45 20 G2A1 1 0 3693 3.2 3347 3.1 38+2 2.7 0 0 0 0
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26 Vinothini 26 4 0 155 67 27.9 G2P1L1 3 1 3994 3.4 3456 3.3 38 2.3 0 0 0 0
27 Deepa 33 5 0 157 96 39 G2A1 1 1 3658 3.3 3434 3.2 37+3 2.94 0 0 0 0
28 Kokila 26 3 0 168 93 32.9 G4P1L1A2 3 0 4193 3.1 3564 2.7 38+3 3.3 0 0 0 0
29 Susuma 19 5 0 150 55 24.4 G2A1 1 0 4546 3 4425 3 37+5 2.75 0 0 0 0
30 Jeya pratha 28 5 0 153 60 25.6 G3P2L2 3 0 4712 3.4 3912 3.4 37+5 2.6 0 0 0 0
31 Nathiya 24 5 0 151 54 23.7 G2A1 1 1 4534 3.5 4097 3.4 39 2.65 1 0 0 3
32 Anjali 33 5 0 153 48 20.5 G2P1L1 2 0 4567 4 3843 3.9 37+6 3.4 0 0 0 0
33 Sumathi 25 4 0 162 55 21 G3P2L1 2 0 4959 3.7 3987 3.6 38+3 2.7 0 0 0 0
34 Sowmiya 25 4 0 156 53 21.8 G2P1L0 2 0 4389 3.5 3745 3.4 40+2 2.8 0 0 0 0
35 Aachal 21 5 1 158 46 18.5 G2A1 3 0 4467 3.5 3705 3.4 37+1 2.7 1 0 0 4
36 Amala 26 3 0 153 53 22.6 G3P1L1A1 3 1 4608 3.8 3984 3.2 39+2 3.1 0 0 0 0
37 Nazreen 32 3 0 158 50 20 G4P2L2A1 2 0 4328 3.6 3668 3.5 38+2 2.95 0 0 0 0
38 Periyanayaki 33 3 0 159 62 24.6 G3A2 1 0 4577 3.4 3632 3.4 38+4 2.75 0 0 0 0
39 Saritha 25 4 1 154 53 22.4 G3P1L1A1 2 1 4045 3.6 3814 3.6 39 2.55 0 0 0 0
40 Sowmiya 26 3 1 156 48 19.7 G3P2L1 3 0 4623 3.8 3517 3.5 40+3 3.3 0 0 0 0
41 Ajitha 24 4 1 150 46 20.4 G2A1 1 1 4667 3.5 3426 3.4 38+1 2.87 0 0 0 0
42 Nandhini 23 4 1 154 58 24.5 G2P1L1 2 0 4290 3.3 3912 3.3 38+6 2.65 0 0 0 0
43 Devi 29 4 1 156 60 24.7 G3P2L2 2 0 4528 3.5 3432 3.2 38+2 2.75 0 0 0 0
44 Shanthi 28 4 0 160 64 26 G2P1L1 3 1 4269 3.2 3901 3.2 39+2 3 0 0 0 0
45 Elayaka 29 4 0 154 60 25.3 G3P2L0 2 0 4233 3 3431 3 37+2 2.8 0 0 0 0
46 Sathya 20 5 0 142 36 18 G2A1 1 1 3241 2.9 2714 2.6 33+6 2 1 0 1 3
47 Nithya 24 5 0 156 51 20.9 G2P1L0 3 1 4352 3.7 3876 3.7 37+5 2.82 0 0 0 0
48 Jeevitha 25 3 0 158 52 20.9 G2P1L1 2 1 4777 3.5 3607 3.4 38+1 3.3 0 0 0 0
49 Archana 26 5 0 154 52 21.9 G3A2 1 1 4758 3.4 3879 3.2 39+5 2.69 0 0 0 0
50 Kavitha 26 4 1 164 59 22 G3A2 1 0 4434 3.6 3980 3.5 38+3 3.3 1 0 0 3
51 Vimal;a 28 4 1 152 46 20 G3P1L1A1 1 0 4653 3.3 3610 3.1 37+4 2.83 0 0 0 0
52 Rajeeswari 42 3 1 155 64 26.7 G4P1L1A2 1 1 4432 3.7 3453 3.7 37+1 2.8 0 0 0 0
53 Sasikala 29 4 1 162 56 21.4 G3P2L1 3 0 3967 3.7 3747 3.4 37+3 3.4 0 0 0 0
54 Santhanalakshmi 30 4 1 152 56 24.3 G3P2L1A1 2 0 4346 3.8 3703 3.5 39 2.7 0 0 0 0
55 Vinothini 27 4 0 149 56 25.2 G3A2 1 1 4936 3.6 4217 3.6 37+3 3.02 0 0 0 0
56 Muneeswari 19 5 0 152 42 18.3 G2A1 1 0 4351 3.7 3673 3.6 37+6 2.6 0 0 0 0
57 Srividhya 28 5 0 159 58 23 G3P1L1A1 3 1 4223 3.5 3650 3.5 38+3 2.55 1 0 0 5
58 Saranya 24 4 0 150 54 24 G3P1L0A1 2 1 3998 3.4 3419 3.3 38 2.8 0 0 0 0
59 Pramela 38 4 1 154 72 30.4 G4P2L1A1 2 0 4129 3.8 3780 3.7 38+4 3.15 0 0 0 0
60 Kamatchi 26 4 1 156 69 28.4 G2A1 1 1 4141 3.4 3997 3.4 37+4 2.64 0 0 0 0
61 Jerina 23 3 0 152 60 26 G2P1L1 2 0 4534 3.7 3645 3.6 39+1 3.08 0 0 0 0
62 Sarumathy 25 4 0 149 54 24.3 G3P2L0 2 1 3291 3 2268 2.7 33+5 2.1 1 0 1 1
63 Deepthi 26 3 1 164 68 25.4 G4P1L1A2 1 1 4396 3.6 3695 3.5 38+4 3.1 0 0 0 0
64 Fausya 24 3 1 154 72 30.4 G2A1 1 0 4592 3.8 3765 3.8 38+1 3.2 0 0 0 0
65 Dhanalakshmi 23 4 1 162 49 18.7 G3P1L1A1 2 1 3303 2.9 2685 2.6 34+1 2.2 1 0 1 1
66 Vijaya 23 4 1 154 60 25.3 G4P2L1A1 3 1 4270 3.2 3442 3.2 38+2 3.3 0 0 0 0
67 Jakera 21 4 0 151 46 20.2 G2A1 1 0 4621 3.7 3789 3.6 39+3 2.94 0 0 0 0
68 Hemavathy 21 4 0 160 42 16.4 G2P1L0 2 1 3432 2.8 2445 2.4 34+3 2.4 1 0 1 3
69 Gayathri 24 3 0 152 60 25.9 G4P1L1A2 1 0 4200 3.7 4054 3.6 40+4 3.4 0 0 0 0
70 Geethalakshmi 25 4 1 156 58 23.8 G4P2L2A1 3 0 3989 3.2 3609 3.2 38+1 2.7 0 0 0 0
71 Kamala 22 4 0 163 46 17.3 G2P1L0 2 0 4380 3.7 3180 3.4 37+2 2.6 0 0 0 0
72 Logeshwari 28 4 1 156 60 24.7 G3P1L0A1 2 0 4498 3.5 4150 3.4 38+6 2.89 0 0 0 0
73 Mohana 27 4 0 153 62 26.4 G5P1L1A3 1 1 4165 3.8 3965 3.7 38+3 2.78 0 0 0 0
74 Seetha 25 4 0 154 65 27.4 G2P1L1 2 1 4452 3.4 3986 3.4 38 2.9 0 0 0 0
75 Devika 35 3 0 161 61 23.5 G3P2L1 2 1 4566 3.5 4005 3.5 38+3 3.3 0 0 0 0
76 Anjali 28 3 0 146 54 25.3 G3P1L1A1 2 0 4034 3.6 3645 3.4 39+4 3.2 0 0 0 0
77 Parameswari 32 4 1 160 62 24.2 G2P1L0 2 0 4536 3.3 3665 3.1 37+5 3.08 0 0 0 0
78 Jothi 28 4 1 163 87 32.8 G2A1 1 0 4841 3.9 4067 3.8 37+6 2.65 0 0 0 0
79 Bhavani 24 5 1 143 50 25 G2P1L0 2 0 4425 3.6 4130 3.7 38+2 3.15 0 0 0 0
80 Murugeshwari 30 3 1 142 55 27.5 G4P2L1A1 2 0 4382 3.8 3763 3.8 39+4 3.2 0 0 0 0
81 Deepa 26 2 1 166 56 20.4 G2P1L1 2 0 4939 3.7 3449 3.6 38+1 2.95 0 0 0 0
1 Smoking 1 NICU Admission 1 Neonatal Complication
0 Not Smoking 0 Not admitted 0 (i) Respitatory Distress
Pregnancy Outcome (ii) Low birth weight
1 0
2 (ii) Preterm 1
3
(iii) Jaundice
(iv) Skin infections
(v) Sepsis
Working
Not Working
Inclusion Criteria 
(i) Abortion between 20 to 28 
Weeks
(ii) Preterm labor
PPROM
(i) Term 
   
 INFORMATION TO PARTICIPANTS 
 
  
INFORMED CONSENT FORM 
 
Title:  “SALIVARY PROGESTERONE AS A BIOCHEMICAL MARKER TO PREDICT 
PRETERM BIRTH IN ASYMPTOMATIC HIGH RISK WOMEN’’ 
 
Name of the Investigator : Dr.M. Mahalakshmi 
Name of the Participant  :                                              
Name of the Institution  : INSTITUTE OF OBSTETRICS AND GYNAECOLOGY,  
     EGMORE, CHENNAI 
 
I _____________________________ have read the information in this form (or it has 
been  read to me). I was free to ask any questions and they have been answered. I am over 18 
years of age and, exercising my free power of choice, hereby give my consent to be included as 
a participant in this study. 
 
1.  I have read and understood this consent form and the information provided to me. 
2.  I have had the consent document explained to me. 
3.  I have been explained about the nature of the study. 
4.  I have been explained about my rights and responsibilities by the investigator. 
5.  I have informed the investigator of all the treatments I am taking or have taken in the past 
months/years   including any native (alternative) treatments.  
6.  I have been advised about the risks associated with my participation in the study.* 
7.  I agree to cooperate with the investigator and I will inform him /her immediately if I suffer 
unusual symptoms. *  
8.  I have not participated in any research study within the past. *  
9.  I am aware of the fact that I can opt out of the study at any time without having to give any 
reasoned this will not affect my future treatment in this hospital. *  
10. I am also aware that the investigators may terminate my participation in the study at any 
time, for any reason, without my consent. *    
11. I hereby give permission to the investigators to release the information obtained from me as 
result of participation in this study to the sponsors, regulatory authorities, Govt. agencies, 
and IEC if required. 
12.  I understand that my identity will be kept confidential if my data are publicly presented.  
13.  I have had my questions answered to my satisfaction.  
14.  I consent voluntarily to participate in the research/study.  
 
I am aware that if I have any question during this study, I should contact the investigator. 
By signing this consent form, I attest that the information given in this document has been clearly 
explained to me and understood by me. I will be given a copy of this consent document. 
 
For adult participants 
1. Name and signature / thumb impression of the participant (or legal representative if  
     participant incompetent) 
 
 
Name ___________________  Signature_________________ Date_______ 
 
 
2. Name and Signature of impartial witness (required for illiterate patients): 
 
Name ______________________ Signature_________________ Date_______ 
 
Address and contact number of the impartial witness: 
 
 
3. Name and Signature of the investigator or his representative obtaining consent: 
 
Name _____________________ Signature_________________ Date_______ 
  

  
   
  
